IMGN - ImmunoGen: A Potential Turnaround Story For 2020
Today we will see why ImmunoGen (IMGN) can be an attractive pick in 2020.
Company overview
ImmunoGen is a clinical-stage biopharmaceutical company focused on the development of next-generation ADCs (antibody-drug conjugates) to target multiple cancer indications. The company’s lead investigational asset, mirvetuximab soravtansine, is being evaluated in women suffering from folate receptor alpha high platinum-resistant ovarian cancer who have been previously treated with Avastin. The company is also studying early-stage investigational ADC, IMGN632, in hematologic malignancies.
ImmunoGen seems to have learned quite a lot from the failed FORWARD I trial
Platinum-resistant ovarian cancer